Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Kim N.(Asian Institute of Technology), Celio Kussumoto, Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center), Eric J. Small(CancerCare Manitoba), Jorge Salinas(Palo Alto University), Gary Mason, Bogdan Żurawski, Esteban Metrebián, V.S. Sakalo(State Institution «Academician O.F.Vozianov Institute of Urology of the National Academy of Medical Sciences of Ukraine»), Michelle Morris, Angela Lopez‐Gitlitz(Janssen (United States)), Gabriela Gatica, Andrea Juliana Gomes, Brooke Diorio(Janssen (United States)), Elizabeth Hovey, Peter Francis(Janssen (United States)), Daphne Wu(Janssen (United States)), Howard Gurney(Radboud University Nijmegen), Martín Greco, Tsvetanka Tosheva, Matos Marco, Marcelo Tatangelo, Livia Andrade, Ji Youl Lee(The Catholic University of Korea Seoul St. Mary's Hospital), Shahneen Sandhu(The University of Melbourne), Gavin Marx, Alejandro Salvatierra, Guilhem Roubaud(Institut Bergonié), Ariel Galapo Kann, David Olmos(Spanish National Cancer Research Centre), Fábio Franke(National Cancer Center), Ali Tafreshi, Eleni Efstathiou(The University of Texas MD Anderson Cancer Center), Anthony M. Joshua(St Vincent's Hospital Sydney), George Wang(Janssen (United States)), David Pook, Matthew R. Smith(Harvard University), María Alejandra Álvarez, Ernesto Korbenfeld(Harbin Medical University), Felipe Melo Cruz(Instituto Brasileiro de Controle do Câncer), Marniza Saad(University of Malaya), Luiza Dib Batista Bugiato Faria, Thean Hsiang Tan, Tom Ferguson, Gerhardt Attard(London Cancer), Siobhan Ng(St John of God Subiaco Hospital), J. M. L. Figueiredo
Journal of Clinical Oncology
March 23, 2023
Cited by 317


Related Papers